The regulatory role and mechanism of microRNA in cholestasis

Linlin WANG; Zhengwang ZHU; Jinghan ZHAO; Ruixue MA; Bing WANG; Pingsheng ZHU; Mingsan MIAO

doi:10.12449/JCH251034

Volume 41 Issue 10

Oct. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(10): 2187-2194

PDF( 1188 KB)

The regulatory role and mechanism of microRNA in cholestasis

DOI: 10.12449/JCH251034

Linlin WANG^{1, 2},
Zhengwang ZHU^{1, 2},
Jinghan ZHAO^{1, 2},
Ruixue MA¹,
Bing WANG³,
Pingsheng ZHU^{1
,
,
,},
Mingsan MIAO²

1.
The First Clinical Medical College of Henan University of Chinese Medicine，Zhengzhou 450046，China
2.
Henan Provincial Collaborative Innovation Center of Research and Development on the Whole Industry Chain of Yu-Yao，Zhengzhou 450046，China
3.
Department of Traditional Chinese Medicine，Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai 200233，China

Research funding:

General Project of National Natural Science Foundation of China (82074340);

Scientific Research Project of Traditional Chinese Medicine for “Double First-Class” Discipline Establishment in Henan Province (HSRP-DFCTCM-2023-1-19);

Scientific Research Project of Traditional Chinese Medicine for “Double First-Class” Discipline Establishment in Henan Province (HSRP-DFCTCM-2023-8-31);

Scientific Research Project of Traditional Chinese Medicine for “Double First-Class” Discipline Establishment in Henan Province (HSRP-DFCTCM-2023-8-32)

More Information

Corresponding author: ZHU Pingsheng， zhupingsheng@126.com （ORCID： 0009-0002-1678-392X）
Received Date: 2025-03-02
Accepted Date: 2025-05-09
Published Date: 2025-10-25

Abstract

Abstract

As a type of endogenous small non-coding RNA， microRNA （miRNA） can regulate gene expression and thereby intervene against the development and progression of cardiovascular diseases， neurodegenerative diseases， metabolic diseases， and autoimmune diseases. The pathogenesis of cholestasis is complex and is mainly associated with the metabolism and transport of bile acids， oxidative stress， inflammatory response， and intestinal flora. Currently， ursodeoxycholic acid is the preferred drug for the clinical treatment of cholestasis， but it may cause adverse reactions and exhibit poor efficacy in some patients. Studies have shown that miRNA can intervene in the disease process of cholestasis through multiple mechanisms such as regulating bile acid metabolism and transport， alleviating oxidative stress， inhibiting inflammatory response， improving cholangiocyte proliferation， and regulating intestinal flora. It can be used as a new biomarker and action target for cholestasis， with high research potential and value. Therefore， this article summarizes the role and mechanisms of miRNA in regulating cholestasis in recent years， in order to provide a reference for further research on the prevention and treatment of cholestasis by targeting miRNA.
- Cholestasis,
- MicroRNAs,
- Gene Expression Regulation

FullText(HTML)

References(55)

References

[1]	National Center for Clinical Research of Infectious Diseases. Expert consensus on the diagnosis and treatment of intrahepatic cholestasis(2021 edition)[J]. Chin J Clin Infect Dis, 2021, 14( 6): 401- 412. DOI: 10.3760/cma.j.issn.1674-2397.2021.06.001. 国家感染性疾病临床医学研究中心. 肝内胆汁淤积症诊治专家共识(2021版)[J]. 中华临床感染病杂志, 2021, 14( 6): 401- 412. DOI: 10.3760/cma.j.issn.1674-2397.2021.06.001.
[2]	CIFUENTES-SILVA E, CABELLO-VERRUGIO C. Bile acids as signaling molecules: Role of ursodeoxycholic acid in cholestatic liver disease[J]. Curr Protein Pept Sci, 2024, 25( 3): 206- 214. DOI: 10.2174/1389203724-666230818092800.
[3]	SUN XL, HU X, ZHANG YT. Clinical application of ursodeoxycholic acid[J]. Chin J Pharmacovigil, 2022, 19( 10): 1149- 1153. DOI: 10.19803/j.1672-8629.20210604. 孙雪林, 胡欣, 张亚同. 熊去氧胆酸的临床应用进展[J]. 中国药物警戒, 2022, 19( 10): 1149- 1153. DOI: 10.19803/j.1672-8629.20210604.
[4]	MA HT, TANG YM. Research advances in exosomes in primary biliary cholangitis[J]. J Clin Hepatol, 2022, 38( 8): 1896- 1900. DOI: 10.3969/j.issn.1001-5256.2022.08.035. 马海涛, 唐映梅. 外泌体在原发性胆汁性胆管炎中作用的研究进展[J]. 临床肝胆病杂志, 2022, 38( 8): 1896- 1900. DOI: 10.3969/j.issn.1001-5256.2022.08.035.
[5]	HO PTB, CLARK IM, LE LTT. MicroRNA-based diagnosis and therapy[J]. Int J Mol Sci, 2022, 23( 13): 7167. DOI: 10.3390/ijms23137167.
[6]	SEARLES CD. MicroRNAs and cardiovascular disease risk[J]. Curr Cardiol Rep, 2024, 26( 2): 51- 60. DOI: 10.1007/s11886-023-02014-1.
[7]	VAGHF A, KHANSARINEJAD B, GHAZNAVI-RAD E, et al. The role of microRNAs in diseases and related signaling pathways[J]. Mol Biol Rep, 2022, 49( 7): 6789- 6801. DOI: 10.1007/s11033-021-06725-y.
[8]	KAGAWA T, SHIRAI Y, ODA S, et al. Identification of specific microRNA biomarkers in early stages of hepatocellular injury, cholestasis, and steatosis in rats[J]. Toxicol Sci, 2018, 166( 1): 228- 239. DOI: 10.1093/toxsci/kfy200.
[9]	MARIN JJG, BUJANDA L, BANALES JM. MicroRNAs and cholestatic liver diseases[J]. Curr Opin Gastroenterol, 2014, 30( 3): 303- 309. DOI: 10.1097/MOG.0000000000000051.
[10]	YOKODA RT, RODRIGUEZ EA. Review: Pathogenesis of cholestatic liver diseases[J]. World J Hepatol, 2020, 12( 8): 423- 435. DOI: 10.4254/wjh.v12.i8.423.
[11]	FUCHS CD, TRAUNER M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 7): 432- 450. DOI: 10.1038/s41575-021-00566-7.
[12]	GHANBARINEJAD V, OMMATI MM, JIA ZP, et al. Disturbed mitochondrial redox state and tissue energy charge in cholestasis[J]. J Biochem Mol Toxicol, 2021, 35( 9): e22846. DOI: 10.1002/jbt.22846.
[13]	CHEN J, ZHANG SJ. The role of inflammation in cholestatic liver injury[J]. J Inflamm Res, 2023, 16: 4527- 4540. DOI: 10.2147/JIR.S430730.
[14]	YU LL, LIU YR, WANG SH, et al. Cholestasis: Exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies[J]. Gut Microbes, 2023, 15( 1): 2181930. DOI: 10.1080/19490976.2023.2181930.
[15]	ERICE O, MUNOZ-GARRIDO P, VAQUERO J, et al. MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation[J]. Hepatology, 2018, 67( 4): 1420- 1440. DOI: 10.1002/hep.29533.
[16]	HONG L, ZHU XL, HANG C, et al. The diagnostic value of CG, LAP and miR-155 in intrahepatic cholestasis of pregnancy and relationship with disease severity[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 12): 1069- 1072, 1077. DOI: 10.3969/j.issn.1005-0264.2023.012.004. 洪雷, 朱晓丽, 杭楚, 等. CG、LAP与miR-155对妊娠期肝内胆汁淤积症的诊断价值及与疾病严重程度的关系[J]. 中西医结合肝病杂志, 2023, 33( 12): 1069- 1072, 1077. DOI: 10.3969/j.issn.1005-0264.2023.012.004.
[17]	BALASUBRAMANIYAN N, DEVEREAUX MW, ORLICKY DJ, et al. Up-regulation of miR-let7a-5p leads to decreased expression of ABCC2 in obstructive cholestasis[J]. Hepatol Commun, 2019, 3( 12): 1674- 1686. DOI: 10.1002/hep4.1433.
[18]	SONG CW, QIU W, ZHOU XQ, et al. Elevated hepatic MDR3/ABCB4 is directly mediated by miR-378a-5p in human obstructive cholestasis[J]. Eur Rev Med Pharmacol Sci, 2019, 23( 6): 2539- 2547. DOI: 10.26355/eurrev_201903_17402.
[19]	BALASUBRAMANIYAN N, DEVEREAUX MW, ORLICKY DJ, et al. miR-199a-5p inhibits the expression of ABCB11 in obstructive cholestasis[J]. J Biol Chem, 2021, 297( 6): 101400. DOI: 10.1016/j.jbc.2021.101400.
[20]	KIM YC, JUNG H, SEOK S, et al. MicroRNA-210 promotes bile acid-induced cholestatic liver injury by targeting mixed-lineage leukemia-4 methyltransferase in mice[J]. Hepatology, 2020, 71( 6): 2118- 2134. DOI: 10.1002/hep.30966.
[21]	CHEN PC, HSU CP, WANG SY, et al. miR-194 up-regulates cholesterol 7 alpha-hydroxylase expression via β-catenin signaling and aggravates cholestatic liver diseases[J]. Am J Pathol, 2023, 193( 6): 755- 768. DOI: 10.1016/j.ajpath.2023.02.007.
[22]	AFONSO MB, RODRIGUES PM, SIMÃO AL, et al. miRNA-21 ablation protects against liver injury and necroptosis in cholestasis[J]. Cell Death Differ, 2018, 25( 5): 857- 872. DOI: 10.1038/s41418-017-0019-x.
[23]	NABIH ES, EL-KHARASHI OA. Targeting HMGB1/TLR4 axis and miR-21 by rosuvastatin: Role in alleviating cholestatic liver injury in a rat model of bile duct ligation[J]. Naunyn Schmiedebergs Arch Pharmacol, 2019, 392( 1): 37- 43. DOI: 10.1007/s00210-018-1560-y.
[24]	KENNEDY LL, MENG FY, VENTER JK, et al. Knockout of microRNA-21 reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated mice[J]. Lab Invest, 2016, 96( 12): 1256- 1267. DOI: 10.1038/labinvest.2016.112.
[25]	XIAO YT, WANG J, YAN WH, et al. Dysregulated miR-124 and miR-200 expression contribute to cholangiocyte proliferation in the cholestatic liver by targeting IL-6/STAT3 signalling[J]. J Hepatol, 2015, 62( 4): 889- 896. DOI: 10.1016/j.jhep.2014.10.033.
[26]	SONG YF, TRAN M, WANG L, et al. miR-200c-3p targets SESN1 and represses the IL-6/AKT loop to prevent cholangiocyte activation and cholestatic liver fibrosis[J]. Lab Invest, 2022, 102( 5): 485- 493. DOI: 10.1038/s41374-021-00710-6.
[27]	SANTOS AA, AFONSO MB, RAMIRO RS, et al. Host miRNA-21 promotes liver dysfunction by targeting small intestinal Lactobacillus in mice[J]. Gut Microbes, 2020, 12( 1): 1- 18. DOI: 10.1080/19490976.2020.1840766.
[28]	CHIANG JYL. Bile acid metabolism and signaling[J]. Compr Physiol, 2013, 3( 3): 1191- 1212. DOI: 10.1002/cphy.c120023.
[29]	VITALE G, MATTIACCIO A, CONTI A, et al. Molecular and clinical links between drug-induced cholestasis and familial intrahepatic cholestasis[J]. Int J Mol Sci, 2023, 24( 6): 5823. DOI: 10.3390/ijms24065823.
[30]	STÄTTERMAYER AF, HALILBASIC E, WRBA F, et al. Variants in ABCB4(MDR3) across the spectrum of cholestatic liver diseases in adults[J]. J Hepatol, 2020, 73( 3): 651- 663. DOI: 10.1016/j.jhep.2020.04.036.
[31]	NAYAGAM JS, WILLIAMSON C, JOSHI D, et al. Review article: Liver disease in adults with variants in the cholestasis-related genes ABCB11, ABCB4 and ATP8B1[J]. Aliment Pharmacol Ther, 2020, 52( 11-12): 1628- 1639. DOI: 10.1111/apt.16118.
[32]	LIU HT, IROBALIEVA RN, KOWAL J, et al. Structural basis of bile salt extrusion and small-molecule inhibition in human BSEP[J]. Nat Commun, 2023, 14( 1): 7296. DOI: 10.1038/s41467-023-43109-1.
[33]	WANG K, ZHANG YC, WANG GJ, et al. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid[J]. Med Res Rev, 2024, 44( 2): 568- 586. DOI: 10.1002/med.21991.
[34]	ANANTHANARAYANAN M, LI YF, SURAPUREDDI S, et al. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical for NR activation of bile acid transporter genes and is downregulated in cholestasis[J]. Am J Physiol Gastrointest Liver Physiol, 2011, 300( 5): G771- G781. DOI: 10.1152/ajpgi.00499.2010.
[35]	XU D, YIN MJ, WANG YM, et al. Research progress on the regulation of FXR-CYP7A1 axis in cholestatic liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 5): 470- 473. DOI: 10.3969/j.issn.1005-0264.2021.05.025. 徐懂, 尹美君, 王钰铭, 等. FXR-CYP7A1轴在胆汁淤积性肝病中的调控研究进展[J]. 中西医结合肝病杂志, 2021, 31( 5): 470- 473. DOI: 10.3969/j.issn.1005-0264.2021.05.025.
[36]	CARSON MD, NEJAK-BOWEN K. Wnt/β-catenin signaling in liver pathobiology[J]. Annu Rev Pathol, 2025, 20( 1): 59- 86. DOI: 10.1146/annurev-pathmechdis-111523-023535.
[37]	HEIDARI R, NIKNAHAD H. The role and study of mitochondrial impairment and oxidative stress in cholestasis[J]. Methods Mol Biol, 2019, 1981: 117- 132. DOI: 10.1007/978-1-4939-9420-5_8.
[38]	YANG HJ, LUO FY, WEI Y, et al. TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway[J]. Ann Transl Med, 2021, 9( 14): 1158. DOI: 10.21037/atm-21-2631.
[39]	O’BRIEN KM, ALLEN KM, ROCKWELL CE, et al. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis[J]. Am J Pathol, 2013, 183( 5): 1498- 1507. DOI: 10.1016/j.ajpath.2013.07.019.
[40]	DAS K, RAO LVM. The role of microRNAs in inflammation[J]. Int J Mol Sci, 2022, 23( 24): 15479. DOI: 10.3390/ijms232415479.
[41]	ZHANG YD, LIU Y, HUO W, et al. The role of miRNA and long noncoding RNA in cholestatic liver diseases[J]. Am J Pathol, 2024, 194( 6): 879- 893. DOI: 10.1016/j.ajpath.2024.02.006.
[42]	ABDELFATTAH AM, MAHMOUD SS, EL-WAFAEY DI, et al. Diacerein ameliorates cholestasis-induced liver fibrosis in rat via modulating HMGB1/RAGE/NF-κB/JNK pathway and endoplasmic reticulum stress[J]. Sci Rep, 2023, 13( 1): 11455. DOI: 10.1038/s41598-023-38375-4.
[43]	SALAS-SILVA S, SIMONI-NIEVES A, CHÁVEZ-RODRÍGUEZ L, et al. Mechanism of cholangiocellular damage and repair during cholestasis[J]. Ann Hepatol, 2021, 26: 100530. DOI: 10.1016/j.aohep.2021.100530.
[44]	WOOLBRIGHT BL, JAESCHKE H. Inflammation and cell death during cholestasis: The evolving role of bile acids[J]. Gene Expr, 2019, 19( 3): 215- 228. DOI: 10.3727/105221619X15614873062730.
[45]	DENG DJ, LI L, WANG CT, et al. Effect and mechanism of osthole on proliferation and apoptosis in human intrahepatic cholangiocarcinoma HuCCT1 cells[J]. Chin J Exp Tradit Med Formulae, 2023, 29( 20): 54- 60. DOI: 10.13422/j.cnki.syfjx.20222423. 邓冬杰, 李励, 王楚婷, 等. 蛇床子素对人肝内胆管癌HuCCT1细胞增殖与凋亡的影响及其机制[J]. 中国实验方剂学杂志, 2023, 29( 20): 54- 60. DOI: 10.13422/j.cnki.syfjx.20222423.
[46]	WANG JZ, LI WX, HUANG JF, et al. Expression of pan-TRK protein in intrahepatic cholangiocarcinoma and its correlation with Ki67[J]. Guangdong Med J, 2023, 44( 10): 1250- 1253. DOI: 10.13820/j.cnki.gdyx.20231879. 王见璋, 李炜霞, 黄金凤, 等. pan-TRK蛋白在肝内胆管细胞癌中的表达及其与Ki67的相关性[J]. 广东医学, 2023, 44( 10): 1250- 1253. DOI: 10.13820/j.cnki.gdyx.20231879.
[47]	ABE M, YOSHIDA T, AKIBA J, et al. STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury[J]. World J Gastroenterol, 2017, 23( 37): 6833- 6844. DOI: 10.3748/wjg.v23.i37.6833.
[48]	HAIDUROV A, ZHELTUKHIN AO, SNEZHKINA AV, et al. p53-regulated SESN1 and SESN2 regulate cell proliferation and cell death through control of STAT3[J]. Cell Commun Signal, 2025, 23( 1): 105. DOI: 10.1186/s12964-025-02104-3.
[49]	ALPINI G, GLASER S, ALVARO D, et al. Bile acid depletion and repletion regulate cholangiocyte growth and secretion by a phosphatidylinositol 3-kinase-dependent pathway in rats[J]. Gastroenterology, 2002, 123( 4): 1226- 1237. DOI: 10.1053/gast.2002.36055.
[50]	KAUR S, BANSAL Y, KUMAR R, et al. A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors[J]. Bioorg Med Chem, 2020, 28( 5): 115327. DOI: 10.1016/j.bmc.2020.115327.
[51]	FARDI F, KHASRAGHI LB, SHAHBAKHTI N, et al. An interplay between non-coding RNAs and gut microbiota in human health[J]. Diabetes Res Clin Pract, 2023, 201: 110739. DOI: 10.1016/j.diabres.2023.110739.
[52]	LIU LS, WANG YL, YU SC, et al. Transforming growth factor beta promotes inflammation and tumorigenesis in Smad4-deficient intestinal epithelium in a YAP-dependent manner[J]. Adv Sci(Weinh), 2023, 10( 23): e2300708. DOI: 10.1002/advs.202300708.
[53]	JIAN YP, YANG G, ZHANG LH, et al. Lactobacillus plantarum alleviates irradiation-induced intestinal injury by activation of FXR-FGF15 signaling in intestinal epithelia[J]. J Cell Physiol, 2022, 237( 3): 1845- 1856. DOI: 10.1002/jcp.30651.
[54]	XU BL, CHENG Y, WEI Y. The role of competitive endogenous RNA in the development of cholangiocarcinoma[J]. J Clin Hepatol, 2022, 38( 11): 2659- 2662. DOI: 10.3969/j.issn.1001-5256.2022.11.044. 徐宝麟, 成雨, 魏勇. 竞争性内源RNA在胆管细胞癌发生发展中的作用[J]. 临床肝胆病杂志, 2022, 38( 11): 2659- 2662. DOI: 10.3969/j.issn.1001-5256.2022.11.044.
[55]	SHI Y, PAN H. The expression and correlation of microRNA-221, microRNA-34a and microRNA-3614-5p in intrahepatic cholestasis of pregnancy[J]. Matern Child Health Care China, 2023, 38( 12): 2272- 2275. DOI: 10.19829/j.zgfybj.issn.1001-4411.2023.12.036. 时艺, 潘华. 微小RNA-221微小RNA-34a及微小RNA-3614-5p在妊娠期肝内胆汁淤积症中的表达及相关性[J]. 中国妇幼保健, 2023, 38( 12): 2272- 2275. DOI: 10.19829/j.zgfybj.issn.1001-4411.2023.12.036.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (46) PDF downloads(6)

The regulatory role and mechanism of microRNA in cholestasis

DOI: 10.12449/JCH251034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The regulatory role and mechanism of microRNA in cholestasis

DOI: 10.12449/JCH251034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content